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Calcium flux-independent NMDA receptor activity is
required for Aβ oligomer-induced synaptic loss
JH Birnbaum1,2,4, J Bali1,3, L Rajendran1,3, RM Nitsch1 and C Tackenberg*,1,4
Synaptic loss is one of the major features of Alzheimer’s disease (AD) and correlates with the degree of dementia. N-methyl-D-
aspartate receptors (NMDARs) have been shown to mediate downstream effects of the β-amyloid peptide (Aβ) in AD models.
NMDARs can trigger intracellular cascades via Ca2+ entry, however, also Ca2+-independent (metabotropic) functions of NMDARs
have been described. We aimed to determine whether ionotropic or metabotropic NMDAR signaling is required for the induction of
synaptic loss by Aβ. We show that endogenous Aβ as well as exogenously added synthetic Aβ oligomers induced dendritic spine
loss and reductions in pre- and postsynaptic protein levels in hippocampal slice cultures. Synaptic alterations were mitigated by
blocking glutamate binding to NMDARs using NMDAR antagonist APV, but not by preventing ion flux with Ca2+ chelator BAPTA or
open-channel blockers MK-801 or memantine. Aβ increased the activity of p38 MAPK, a kinase involved in long-term depression
and inhibition of p38 MAPK abolished the loss of dendritic spines. Aβ-induced increase of p38 MAPK activity was prevented by
APV but not by BAPTA, MK-801 or memantine treatment highlighting the role of glutamate binding to NMDARs but not Ca2+ flux for
synaptic degeneration by Aβ. We further show that treatment with the G protein inhibitor pertussis toxin (PTX) did not prevent
dendritic spine loss in the presence of Aβ oligomers. Our data suggest that Aβ induces the activation of p38 MAPK and
subsequent synaptic loss through Ca2+ flux- and G protein-independent mechanisms.
Cell Death and Disease (2015) 6, e1791; doi:10.1038/cddis.2015.160; published online 18 June 2015
Alzheimer’s disease (AD) is clinically characterized by cognitive
impairments caused by massive neuronal degeneration and
synaptic loss. The reduction in synapse numbers is the best
neuropathological correlate to the degree of dementia in AD.1
Besides synaptic alterations, the levels of soluble oligomeric
forms of β-amyloid peptide (Aβ) but not plaques correlates best
with memory loss in AD.2 Accumulating evidence indicates that
transgenically produced Aβ or the treatment with Aβ oligomers
decrease dendritic spine density,3–6 impair long-term potentia-
tion (LTP),7 facilitate long-term depression (LTD)8 and induce
aberrant spine morphology.5,9
Although the signaling cascades coupling Aβ with synaptic
degeneration are incompletely understood, experimental
evidence suggests an essential role for N-methyl-D-aspartate
receptors (NMDARs). Oligomeric Aβ can bind to dendritic
spines and treatment with NMDAR antibodies abolishes Aβ
binding.10 Pharmacological inhibition of NMDAR activity also
mitigates the pathological effect of Aβ on synapses.4–6,11
NMDARs are ionotropic receptors permeable for cations and
controlled by a voltage-dependent Mg2+ block that is removed
after membrane depolarization by α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors (AMPARs). Upon
glutamate binding to the NR2 subunit of NMDARs, cations
including Ca2+ enter the cell. It has been thought for a long
time that the levels of Ca2+ influx through NMDARs determine
the induction of either LTP (high Ca2+ influx or LTD (mild Ca2+
influx).12 Nevertheless, a recent study showed that Ca2+ flux
is not essential for the induction of NMDAR-LTD, whereas
glutamate binding to the receptor is required.13 NMDAR
signaling independently of ion flux has already been proposed
to regulate NMDAR phosphorylation and endocytosis.14,15
Further, the subunit switch between NR2B and NR2A
NMDARs is driven by glutamate in the absence of NMDAR
currents.16 However, the role of ion flux for synaptic loss in AD
still remains to be elucidated.
We show that the Aβ-induced pre- and postsynaptic loss is
mediated by glutamate binding to NMDARs, independent of
ion influx.
Results
To determine the mechanisms of synaptic loss by Aβ, we
cultured hippocampal slices from arcAβ-transgenic mice and
infected themwith neurotropic Sindbis virus expressing EGFP
to visualize single neurons. Neurons in transgenic slices
showed reduced dendritic spine densities. Treatment with the
NMDAR antagonist D-APV, which blocks the glutamate-
binding sites, completely abolished spine loss (Figures 1a
and b). This is in agreement with previous findings that the
glutamate-binding site antagonist CPP rescued spine loss in
APP-transgenic cultures.5 As NMDAR signaling has been
reported to be mediated through Ca2+ influx, we sought to
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determine the role of Ca2+ influx for Aβ-induced loss of
dendritic spines. To this end, slices were treated with NMDAR
open-channel blockers memantine or MK-801 (Figure 1c) or
with Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-
tetraacetic acid (BAPTA; Figure 1e). Neither memantine nor
MK-801 nor BAPTA treatment restored spine density in
transgenic cultures (Figures 1d and f). Ca2+ flux through
NMDARs requires the removal of the Mg2+ block within the
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receptor pore, which is achieved upon membrane depolariza-
tion by AMPARs. To analyze the involvement of AMPARs, we
treated cultures with AMPAR antagonist CNQX, but did not
observe any effect on spine numbers in transgenic cultures
(Figures 1g and h). Concentrations of inhibitors were chosen
according to previous reports demonstrating highest degree of
specificity and/or therapeutic relevance (APV and MK-801;17
memantine18,19).
To ensure that memantine, MK-801 and BAPTA prepara-
tions at the used concentrations are functional and can block
NMDARs and the entry of Ca2+, despite having no protective
effect, we performed synaptic activation experiments in the
presence of these compounds. Synaptic activation induced
phosphorylation of extracellular signal regulated kinases
(phospho-ERK, p-ERK), which is in agreement with previous
studies6,20 (Figure 1i). The presence of APV, memantine,
MK-801 or BAPTA fully prevented ERK activation, confirming
the functionality of these compounds (Figure 1j). Of note,
memantine blocked synaptic activation although it has been
described to preferentially block extrasynaptic over synaptic
activity at the used concentration.21
As shown previously, spine loss in arcAβ-transgenic
cultures can be prevented in the presence of anti-Aβ
antibodies,6 confirming that Aβ but not APP or any other
cleavage product is responsible for the observed effects on
spines. Hence, our data indicate that glutamate binding to
NMDARs rather than Ca2+ flux mediates Aβ-induced dendritic
spine loss.
To confirm the morphological spine data, we determined
whether Aβ also affects the levels of pre- and postsynaptic
proteins and analyzed PSD-95 (postsynaptic) and synapto-
physin (presynaptic) levels in lysates of non-transgenic
and arcAβ-transgenic cultures (Figure 2a). Compared with
controls, the levels of both proteins were strongly reduced in
transgenic cultures. Treatment with APV but not with
memantine or MK-801 rescued the reduction of protein levels
(Figure 2b). Likewise, treatment with BAPTA did not affect loss
of synaptic proteins in transgenic cultures (Figures 2c and d).
Synaptic activity has been shown to increase the production
of Aβ and, inversely, preventing synaptic activity can reduce
Aβ production.22 To exclude that the protective effect of APV is
simply based on Aβ reduction, we quantitatively measured the
levels of Aβ40 in the supernatant of arcAβ-transgenic cultures
treated with the respective NMDAR antagonists (Figure 2e)
under identical conditions as in the previous experiments.
NMDAR antagonists did not significantly alter Aβ levels in the
medium of transgenic cultures.
This indicates that, in addition to dendritic spine loss,
reductions in pre- and postsynaptic protein levels are caused
by NMDAR functions, independent of Ca2+ flux.
A recent study showed that activation of p38 MAPK is
essential for Ca2+-independent metabotropic function of
NMDARs.13 We analyzed whether p38 MAPK is also involved
in the Aβ effects on synapses and examined the activity of p38
MAPK in lysates from non-transgenic and arcAβ-transgenic
cultures (Figure 3a). Increased levels of phosphorylated
(active) p38 MAPK (p-p38) were observed in transgenic
cultures. After treatment with APV, the levels of p-p38 were
reduced to control levels, whereas memantine or MK-801
treatment had no effect (Figure 3b). To ascertain that active
p38 MAPK mediates synaptic deficits caused by Aβ, we
treated cultures with the p38 MAPK inhibitor SB239063.
Treatment abolished spine loss in arcAβ-transgenic cultures
(Figures 3c and d). To examine whether a general increase in
synaptic activity in transgenic cultures contributes to
increased p-p38 MAPK levels, we treated non-transgenic
and arcAβ-transgenic cultures with bicuculline and
4-aminopyridine (Figures 3e and f). Synaptic activation
increased levels of p-ERK. No difference in p-ERK levels
were observed between transgenic and non-transgenic
cultures, indicating that arcAβ-transgenic slices display no
general increase in synaptic activity. Further, synaptic activa-
tion does not affect the activity of p38 MAPK.
This data suggests that Aβ induces the activity of p38
MAPK, which mediates the loss of dendritic spines. This effect
does not depend on Ca2+ influx or general synaptic activation.
Oligomeric Aβ is considered to be one of the main toxic Aβ
species in the AD brain. So far, we used cultures from arcAβ-
transgenic mice to determine the effects of Aβ on synapses in
the presence of other APP processing products (Figures 1–3).
Although arcAβ mice show early formation oligomeric Aβ
in vivo,23 the role of oligomeric Aβ for our findings requires
further investigations. To conclusively validate the role of Aβ
oligomers, we treated non-transgenic cultures with defined
preparation of Aβ42 oligomers at sublethal concentrations
(Figure 4). Oligomer preparations contained mostly mono-, tri-
and tetramers as determined by silver stained SDS gel and
western blot (Figure 4k), which is in agreement with previous
studies.24,25 Scrambled Aβ, subjected to the same oligomer-
ization protocol as Aβ42, did not aggregate, as expected.
Treatment with Aβ oligomers but not scrambled Aβ reduced
dendritic spine density to a similar extent as observed in
transgenic cultures (compare Figure 4 and Figure 1). Con-
firming the transgenic data, only APV treatment (Figures 4a
and b) but not memantine (Figures 4c and d), MK-801
(Figures 4e and f) or BAPTA (Figures 4g and h) prevented
Figure 1 Blocking glutamate binding to NMDARs but not Ca2+ influx prevents dendritic spine loss in arcAβ-transgenic slice cultures. (a) Confocal images of dendrites from
CA1 neurons in the stratum radiatum of non-transgenic and arcAβ-transgenic hippocampal slice cultures treated with NMDAR antagonist APV (100 μM). Scale bar: 5 μm. (b)
APV treatment reverses the dendritic spine loss in arcAβ-transgenic cultures. n= 10–13. (c) Confocal images of non-transgenic and arcAβ-transgenic cultures treated with
NMDAR open-channel blocker memantine (1 μM) or MK-801 (30 μM). (d) Neither memantine nor MK-801 treatment reverses spine loss. n= 11–13. (e) Confocal images of
cultures treated with Ca2+ chelator BAPTA (2 mM) or vehicle (BAPTA solvent NaHCO3). (f) BAPTA treatment does not affect spine loss in transgenic cultures. (g) Confocal images
of cultures treated with AMPAR antagonist CNQX (10 μM). (h) CNQX treatment does not affect spine loss in transgenic cultures. n= 11–15. (i) Western blot of lysate from non-
transgenic cultures after synaptic activation—in the presence of the reagents used above—showing phosphorylated and total ERK levels. (j) APV (100 μM), memantine (1 μM),
MK-801 (30 μM) and BAPTA (2 mM) pre-treatment prevent ERK phosphorylation after synaptic activation. All values are shown as mean±S.E.M.; ***Po0.001; two-tailed
unpaired Student’s t-test; significances show difference to the respective non-transgenic control (b–h) or to non-activated cultures (j). non-tg, non-transgenic; tg, arcAβ
transgenic; Mem, memantine; BAP, BAPTA; MK, MK-801; p-ERK, phospho-ERK
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oligomer-induced spine loss. Oligomeric Aβ further reduced
PSD-95 and synaptophysin levels, which could not be rescued
by BAPTA treatment (Figures 4i and j). Aβ did not cause cell
death at the used concentration (Figure 4l).
This indicates that oligomeric Aβ, similar to transgenically
produced Aβ, exerts its toxic properties on synapses via
NMDAR signaling, independent of Ca2+ influx.
To determine whether Ca2+ flux-independent synaptic loss
depends on G protein signaling, we treated slices with
oligomeric Aβ and pertussis toxin (PTX), an inhibitor of the
heterotrimeric Gi/o protein family, at concentrations described
before in slice cultures.26 PTX administration did not prevent
spine loss caused by Aβ (Figures 5a and b) suggesting that
Aβ-induced synaptic loss does not require a PTX-sensitive
subgroup of G proteins.
Discussion
In this study, we have examined the role of Ca2+ flux for Aβ-
induced loss of dendritic spines and pre- and postsynaptic
proteins. Our data show that NMDAR-dependent ion flux is not
required for synaptic loss, whereas binding of glutamate to the
Figure 2 Blocking glutamate binding to NMDARs but not Ca2+ influx prevents the loss of pre- and postsynaptic markers in arcAβ-transgenic cultures. (a) Representative
western blot of cell lysates from non-transgenic or arcAβ-transgenic cultures after treatment with NMDAR antagonists APV (100 μM), memantine (1 μM) or MK-801 (30 μM).
(b) Quantification of western blots. PSD-95 and synaptophysin levels are strongly reduced in arcAβ-transgenic cultures. APV treatment restores PSD-95 and synaptophysin
signals back to control levels, whereas memantine and MK-801 have no effect. n= 6. (c) Representative western blot of cell lysates from non-transgenic or arcAβ-transgenic
slices after treatment with Ca2+ chelator BAPTA (2 mM) or vehicle (BAPTA solvent NaHCO3). (d) BAPTA treatment does not affect loss of synaptic proteins in transgenic cultures.
n= 6. (e) Aβ40 levels in the supernatant of arcAβ-transgenic cultures after treatment with NMDAR antagonists measured by MSD. Aβ40 production is not influenced by any
NMDAR antagonist. Aβ levels were corrected by protein levels from lysates. n= 3. All values are shown as mean± S.E.M. (*Po0.05, **Po0.01, ***Po0.001; two-tailed
unpaired Student’s t-test; significances indicate differences to the respective non-transgenic control). non-tg, non-transgenic; tg, arcAβ-transgenic; Mem, memantine; MK,
MK-801
Aβ-induced synaptic loss is Ca2+ ﬂux independent
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Figure 3 p38 MAPK is activated in arcAβ-transgenic cultures and mediates spine loss. (a) Representative western blot showing phosphorylated (active) and total p38 MAPK
in lysates non-transgenic or arcAβ-transgenic slices after treatment with different NMDAR antagonists. (b) Quantification shows increased levels of phosphorylated p38 in arcAβ-
transgenic cultures. The increased amounts of phospho-p38 were reduced to control levels by APV (100 μM) but not by memantine (1 μM) or MK-801 (30 μM) treatment. The
non-transgenic untreated control was set to 1. n= 6. (c) Confocal images of dendrites from CA1 neurons in the stratum radiatum of non-transgenic and arcAβ-transgenic
hippocampal slice cultures treated with p38 MAP kinase inhibitor SB239063 (20 μM). Scale bar: 5 μM. (d) SB239063 treatment reverses the dendritic spine loss in arcAβ-
transgenic cultures. n= 14-16. (e) Representative western blot showing activated ERK (p-ERK) and activated p38 (p-p38) in non-transgenic or arcAβ-transgenic slices after
synaptic activation with bicuculline and 4-aminopyridine. (f) Quantification shows increased p-ERK levels after synaptic activation, independent of transgenic background.
Synaptic activation does not affect p-p38 levels. n= 5. All values are shown as mean± S.E.M. (*Po0.05, **Po0.01, ***Po0.001; two-tailed unpaired Student’s t-test;
significances indicate differences to the respective non-tg control; for p-ERK/total ERK significances indicate differences to the respective non-activated culture). non-tg, non-
transgenic; tg, arcAβ transgenic; Mem, memantine; MK, MK-801; p-ERK, phospho-ERK; p-p38, phospho-p38 MAPK; syn, synaptic activation
Aβ-induced synaptic loss is Ca2+ ﬂux independent
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NMDAR is essential for coupling Aβ with synaptic
degeneration.
NMDARs have been thought to signal exclusively iono-
tropic, regulating intracellular signaling via Ca2+ transmission.
However, recent evidence indicates that NMDARs can signal
metabotropically, that is, independent of ion flux. The group of
Roberto Malinow showed that induction of NMDAR-LTD via
activation of p38 MAPK is based on metabotropic signaling.13
Further, the induction of LTD byAβ can occur in the absence of
Ca2+ transmission.17,27 Together, these data suggest that
glutamate binding to NMDARs may induce a conformational
change that subsequently activates intracellular signaling
cascades even in the absence of Ca2+ flux. This possibly does
not exclude an additional role of intracellular Ca2+, because
the injection of Ca2+ chelators into neurons prevents LTD
induction.13,28 In agreement, oligomeric Aβ has been shown to
increase intracellular Ca2+ levels by mobilizing Ca2+ from the
ER rather than promoting influx of Ca2+ from the extracellular
space.29
Our data show that the induction of specific metabotropic-
like NMDAR signaling pathway by Aβ, which is not induced by
general synaptic activation, causes downstream phosphor-
ylation of p38 MAPK. Active p38 MAPK is key player in
NMDAR- and mGluR-dependent LTD30,31 and mediates
AMPAR endocytosis.32 A study by Yang et al.33 described an
intracellular pathway based on the co-activation of mGluR5
and NMDARs, also independent of Ca2+ flux. Further,
mGLuR5 has been implicated in mediating toxic effects of
Aβ at synapses.34,35 Thus, a co-activation of mGluR5 and
NMDARs may cause downstream activation of p38 MAPK
followed by synaptic loss. However, treatment with the G
protein inhibitor PTX did not prevent spine loss in our model,
which renders the involvement of mGluRs unlikely.
In previous studies, we showed that caspase-3 and
calcineurin are essential for the loss of spines by
Aβ.5,6 Caspase-3 can be activated by p38MAPK.36,37 Further,
D’Amelio and colleagues reported caspase-3- and
calcineurin-mediated synaptic dysfunction in APP-transgenic
mice. Importantly, they observed that caspase-3-activated
calcineurin by proteolytic cleavage in a Ca2+-independent
manner, supporting our finding that Aβ-induced synaptic
dysfunction can occur in the absence of Ca2+ flux.
An important finding in our study is the lack of synaptic
protection by memantine as memantine is the only clinical
approved NMDAR antagonist for treatment of AD patients.
Memantine, at clinically relevant low μM concentrations, is a
low-affinity, uncompetitive open-channel blocker with a rela-
tively high off-rate.38 High-affinity NMDAR antagonists may be
toxic after long exposure due to block of synaptic transmission.
However, memantine has been suggested to be more
tolerable because of blocking mainly over-excitation of the
receptor rather than its physiological activity. As the high off-
rate of memantine could still allow Ca2+ influx into the cell, we
confirmed the data using a second open-channel blocker
MK-801 and the Ca2+ chelator BAPTA. Further, all used
compounds could fully block ERK phosphorylation after
synaptic activation. Interestingly, treatment of slices with even
the high-affinity inhibitors D-APVor MK-801 or with BAPTA did
not show any side effects on spines.
Despite having no protective effect for Aβ-induced
synaptic loss in our study, memantine may be more beneficial
Figure 4 Oligomeric Aβ-induced synaptic loss is prevented by APV but not by memantine, MK-801 or BAPTA treatment. (a) Confocal images of dendrites from CA1 neurons
in the stratum radiatum of non-transgenic slice cultures treated with oligomeric Aβ (500 nM) or scrambled Aβ (500 nM) and NMDAR antagonist APV (100 μM). Scale bar: 5 μM.
(b) APV treatment prevents Aβ oligomer-induced dendritic spine loss. n= 13–17. (c) Confocal images of non-transgenic cultures treated with oligomeric Aβ (500 nM) and
NMDAR antagonist memantine (1 μM). (d) Memantine treatment does not prevent spine loss. n= 12–17. (e) Confocal images of cultures treated with oligomeric Aβ (500 nM) and
NMDAR antagonist MK-801 (30 μM). (f) MK-801 treatment does not prevent spine loss. n= 13–15. (g) Non-transgenic cultures treated with Aβ oligomers (500 nM) and Ca2+
chelator BAPTA (2 mM) or vehicle (BAPTA solvent NaHCO3). (h) BAPTA does not prevent spine loss caused by oligomeric Aβ. n= 11–15. (i) Representative western blot of cell
lysates from slices after treatment with Aβ oligomers (500 nM) and Ca2+ chelator BAPTA (2 mM). (j) BAPTA does not prevent reduction in PSD-95 or synaptophysin levels after Aβ
oligomer treatment. n= 6. (k) SDS gel showing oligomeric Aβ preparations and scrambled Aβ after silver staining (right panel) and western blot stained with 6E10 antibody
(left panel). Monomers, tri- and tetramers are observed in the oligomeric preparation, whereas scrambled Aβ only shows monomers. (l) LDH assay showing no toxicity of Aβ
oligomer treatment (500 nM) compared with scrambled Aβ. n= 6. Values are shown as mean± S.E.M. (*Po0.05, **Po0.01, ***Po0.001; two-tailed unpaired Student’s t-test).
Scr. Aβ, scrambled Aβ; AβO, oligomeric Aβ; Mem, memantine
Figure 5 Oligomeric Aβ-induced synaptic loss is not prevented by treatment with
PTX. (a) Confocal images of dendrites from CA1 neurons in the stratum radiatum of
non-transgenic slice cultures treated with oligomeric Aβ (500 nM) or scrambled Aβ
(500 nM) and G protein inhibitor PTX (500 ng/ml). (b) PTX treatment does not prevent
Aβ oligomer-induced dendritic spine loss. n= 12. Values are shown as mean±
S.E.M. (**Po0.01, ***Po0.001; two-tailed unpaired Student’s t-test). Scr. Aβ,
scrambled Aβ; AβO, oligomeric Aβ; PTX, pertussis toxin
Aβ-induced synaptic loss is Ca2+ ﬂux independent
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with respect to other Aβ effects. A recent study showed that
injection of low-molecular-weight (LMW) oligomers into mice
caused persistent memory impairment and synaptic loss,
whereas injection of high-molecular-weight (HMW) oligomers
resulted in neuronal oxidative stress and reversible cognitive
deficits but no synaptic loss. Memantine treatment could
rescue only the effects of HMW but not LMW Aβ oligomers,39
further indicating that memantine may not be beneficial with
respect to Aβ-induced synaptic alterations. However, mem-
antine protected against the induction of oxidative stress by
oligomeric Aβ10 and studies from our lab showed that
memantine, at the concentration used in this study, prevented
the increase in tau phosphorylation by Aβ (unpublished
observations).
Because synaptic loss occurs early in the disease
process,40 our data my contribute to explain why memantine
is ineffective in treating early-staged mild AD patients.41
Together, our data establish a Ca2+ flux- and G
protein-independent NMDAR signaling pathway coupling
Aβ toxicity with p38 MAPK activation and synapse
loss, suggesting pharmacological inhibition of this pathway
as a potent mechanism to prevent Aβ-mediated
early synaptic loss.
Materials and Methods
Chemicals/reagents. Cell culture reagents were purchased from Sigma
(Schnelldorf, Germany) and Invitrogen (Basel, Switzerland). NMDA receptor
antagonists D-APV (also called D-AP5, D-2-amino-5-phosphonovalerate; Batch
No.:71), MK-801 ((5 S,10 R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohep-
ten-5,10-imine maleate; Batch No.:8), memantine (3,5-dimethyl-tricyclo[3.3.1.13,7]
decan-1-amine hydrochloride; Batch No.:9), Ca2+ chelator BAPTA (Batch No.:4),
AMPA receptor antagonist CNQX (6-cyano-7-nitroquinoxaline-2,3-dione; Batch
No.:33) were purchased from Tocris (Bristol, UK). PTX was purchased from List
Biological Laboratories (Campbell, CA, USA).
Hippocampal slice cultures. ArcAβ-transgenic mice were obtained as
described.23 All animal experiments were performed in accordance with the
guidelines of the Swiss veterinary cantonal office. Hippocampal slice cultures were
prepared and cultured as described.42 In short, 6–7-day-old transgenic and non-
transgenic C57BL/6 mice were decapitated, brains were removed, hippocampi were
isolated and cut into 400-μm thick slices. Slices were cultured in culture medium
(minimum essential medium Eagle with HEPES modification, 25% basal medium
with Earle’s modification, 25% heat-inactivated horse serum, 2 mM glutamine, 50
units per ml penicillin, 50 μg/ml streptomycin, 0.6% glucose, pH 7.2). Culture
medium was exchanged every second or third day. On DIV 11, culture medium was
replaced by low-serum Nb-N2 medium (Neurobasal medium, 0.5% heat-inactivated
horse serum, 2 mM glutamine, 50 units per ml penicillin, 50 μg/ml streptomycin,
0.6% glucose, 1 × N2 supplement, pH 7.2) to ensure more defined condition during
analysis. For spine analysis, slice cultures were infected with Sindbis virus
expressing EGFP on DIV 12 in culture and fixed on DIV 15 with 4%
paraformaldehyde/sucrose. For protein analysis, uninfected slices were lysed on
DIV 15 in culture.
Treatments. To determine inhibitor effects in transgenic cultures, slices were
treated with respective inhibitors from DIV 11–15. To analyze effects of oligomeric
Aβ, slices were treated with Aβ oligomers or scrambled Aβ from DIV 11–15. To
assess the effects of inhibitors on cultures exposed to oligomeric Aβ, slices were
treated with Aβ oligomers and the respective inhibitor in parallel from DIV 11–15.
For treatment with PTX, slices were exposed to PTX from DIV 13–15.
Dendritic spine analysis. To determine dendritic spine density, virus solution
was diluted to achieve 1–10 infected neurons per slice to allow imaging of single
dendritic fragments. Analysis of dendritic spine density was performed using Leica
SP2 CLSM equipped with 63 × objective (NA: 1.2) and 488-nm Argon laser. Apical
dendritic segments in CA1 stratum radiatum were imaged with size of 30 × 30 μm
(512 × 512 pixel, voxel size: 0.05813 × 0.05813 × 0.25 μm). Image stacks were
processed to maximum projections, and dendritic spine density was determined
using ImageJ.
Spine imaging and counting were performed blinded (without the researcher
knowing the mouse genotype or culture treatment).
Synaptic activation protocol. Stimulation of synaptic activity was
adapted from Tackenberg et al.6 Cultures were pretreated with APV, memantine,
MK-801 or BAPTA for 12 h before activation. Then, cultures were exposed to
neurobasal medium containing 1 mM 4-AP, 25 mM bicuculline and the respective
inhibitor for 20 min. Control cultures were treated with neurobasal medium
containing identical DMSO concentrations as above but devoid of 4-AP, bicuculline
and inhibitors.
Western blot. Cultured slices were harvested on DIV 15, sonicated in RIPA
buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5% deoxycholate
and 0.1% SDS, pH 8.0) containing phosphatase inhibitor cocktails 1 and 2 (Sigma)
and protease inhibitor cocktail (Roche, Basel, Switzerland) and centrifuged at
5000 g for 10 min at 4 °C. The supernatant was stored at − 80 °C. Lysates were
subjected to SDS-PAGE followed by immunoblotting using primary antibodies
against PSD-95 and Synaptophysin (both Millipore, Billerica, MA, USA, 1 : 1000),
phospho-p38 MAPK and p38 MAPK (both Cell Signaling, Danvers, MA, USA,
1 : 1000), 6E10 (Signet, Dedham, MA, USA, 1 : 500) and GAPDH (Biodesign, Saco,
ME, USA, 1 : 5000). Band intensities were quantified with ImageJ.
Silver staining. Oligomeric Aβ42 preparations were analyzed by SDS-PAGE.
The gel was left overnight in fixing solution (40% EtOH, 10% acetic acid), sensitized
in 0.017% sodium thiosulfate for 2 min, impregnated in 0.27% silver nitrate solution
(including 0.37% formaldehyde) for 30 min and developed in 0.03 M sodium
carbonate (supplemented with 0.15% formaldehyde and 0.02% sodium thiosulfate).
The reaction was stopped in 3% glacial acid.
Aβ oligomer preparations. Synthetic Aβ42 peptide was obtained from
American peptide. Preparation of Aβ42 oligomers (Abeta-derived diffusible ligands)
was carried out as previously described.43 Cold 1,1,1,3,3,3-hexafluro-2-propanol
(HFIP) was added to Aβ42 peptide to a final concentration of 1 mM. HFIP was
evaporated overnight, peptides dried for 10 min in a speedvac and stored at − 80 °C.
Peptides were resuspended in DMSO at 5 mM concentrations. Neurobasal medium
without phenol red was added to achieve a peptide concentration of 100 μM and
incubated for 24 h at 4 °C. Higher aggregates, for example, fibrils were removed by
centrifugation at 14 000 g for 10 minutes at 4 °C and the supernatant was used for
experimental procedures. Aβ42 oligomer preparations were analyzed by silver
staining and western blot for each experiment.
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